Delivery Order SPE2DB22D3501-SPE2DB25FXN94
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,023.86 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price, non-set-aside delivery order is scheduled for completion by September 9, 2025, with performance at AmerisourceBergen's headquarters in Conshohocken, Pennsylvania. Repatha (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in eligible patient...
- The Defense Logistics Agency awarded a delivery order valued at $5,997.38 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 29, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, supplying brand-name and generic...
- The Defense Logistics Agency awarded a delivery order valued at $4,865.12 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 22, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical supply vendor. The contract represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 23, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of July 23, 2025. This non-competitive, firm fixed-price delivery order was issued on July 22, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Repatha is a prescription medication used to treat high cholesterol and reduce the risk of cardiovascular disease. This...
- The Defense Logistics Agency awarded a delivery order valued at $13,727.57 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens. This non-competitive, firm fixed-price delivery order was awarded on September 9, 2025, with a completion date of September 10, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Repatha (evolocumab) is a PCSK9 inhibitor used to lower cholesterol and reduce cardiovascular risk in eligible...
- The Defense Logistics Agency awarded a $3,783.70 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price, competitively awarded contract was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Repatha is a prescription medication used to lower cholesterol...
- The Defense Logistics Agency awarded a delivery order valued at $4,540.44 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price delivery order represents a non-competitive award issued under an existing contract vehicle and is scheduled for completion by August 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its...
- The Defense Logistics Agency awarded a delivery order valued at $17,139.13 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors. The contract, awarded on September 9, 2025, with completion targeted for September 10, 2025, operates under a firm fixed-price delivery order structure with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this order. Repatha...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXN94Delivery Order
The Defense Logistics Agency awarded a $1,135.11 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 29, 2025. This is a firm fixed-price delivery order issued under a competitive, non-set-aside procurement. The award was made to AmerisourceBergen's Corporate Office, located in Conshohocken, Pennsylvania, the company's headquarters. Repatha (evolocumab) is a PCSK9 inhibitor prescribed for cholesterol management, typically utilized within military and veteran healthcare systems supported by the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued as a child contract under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products, medical supplies, vaccines, and specialty medications to support military healthcare programs worldwide. The company's extensive federal contract portfolio demonstrates its critical role as a major pharmaceutical distributor for the Department of Defense and other federal healthcare systems, with consistent competitively-awarded delivery orders reflecting its capability to meet diverse medical procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/26/25 |